GIGA 2050
Alternative Names: GIGA-2050; rCIG; Recombinant anti-coronavirus 19 hyperimmune gammaglobulin; Recombinant anti-coronavirus 19 hyperimmune gammaglobulin therapy - GiaGen; Recombinant polyclonal antibodies - GigaGen; Recombinant polyclonal antibody therapy - GigaGenLatest Information Update: 28 Jun 2024
At a glance
- Originator GigaGen
- Class Antivirals; Polyclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (IV)
- 01 Nov 2022 ProteoNic extends the license agreement with GigaGen for its 2G UnicTM technology platform
- 11 Jan 2022 GigaGen terminates a phase I trial in COVID-2019 infections in USA due to commercial reasons (NCT04883138)